The New York Times reports:
Two doses of a new Covid vaccine that is based on a conventional approach achieved 100 percent efficacy against severe disease and hospitalizations, and it could be an effective booster after other Covid shots, the vaccine’s manufacturers announced on Wednesday.
The vaccine, made by the Europe-based pharmaceutical companies Sanofi and GSK, is one of four candidates that received billions of dollars for development from Operation Warp Speed, the Trump administration’s program to accelerate vaccines.
Used as a booster dose after one of the other available coronavirus vaccines, the Sanofi-GSK shot increased antibody levels by 18- to 30-fold.
Read the full article.
Covid Live Updates: Sanofi-GSK Vaccine Results Show 100% Efficacy Against Severe Disease, Its Makers Say https://t.co/CVyZHuKzNC
— Business News (@Busines65959783) February 23, 2022